Skip to main content
Premium Trial:

Request an Annual Quote

Lazard Places 'Buy' Rating on Sequenom Stock

NEW YORK (GenomeWeb News) – Investment firm Lazard Capital today initiated coverage of Sequenom’s stock with a “Buy” rating and a price target of $20.
 
Sequenom’s shares were trading up 3.2 percent at $7.79 in early Friday trading on the Nasdaq.
 
Lazard’s price target is based on the market potential for non-invasive prenatal diagnostic tests being developed by Sequenom. The San Diego-based firm is developing a test for Down syndrome, and Lazard expects Sequenom to present positive data next week on studies of that test.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.